Yahoo Web Search

  1. Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up

    Zacks via Yahoo FinanceAug 06 14:19 PM

    Allergan plc’s AGN second-quarter adjusted earnings came in at $4.38 per share, which beat the Zacks Consensus Estimate of $4.34 and came within the guided range of $4.20 and $4.40. Revenues ...

  2. Why AbbVie (ABBV) is a Great Dividend Stock Right Now

    Zacks via Yahoo FinanceAug 09 13:15 PM

    Based in North Chicago, AbbVie (ABBV) is in the Medical sector, and so far this year, shares have seen a price change of -29.01%. Over the last 5 years, AbbVie has increased its ...

  3. Some investors have raised concerns about Merck over-reliance on Keytruda and have looked for a large deal to lessen that dependence, along the lines of AbbVie's $63 billion deal for ...

  4. California-based Gilead said it now expects 2019 sales of $21.6 billion to $22.1 billion in 2019, up from its prior forecast of $21.3 billion to $21.8 billion. The biotechnology company said ...

  5. Amgen (AMGN) Q2 Earnings & Sales Beat, New Drugs Shine

    Zacks via Yahoo FinanceJul 31 13:34 PM

    Amgen AMGN reported second-quarter 2019 earnings of $3.97 per share, which beat the Zacks Consensus Estimate of $3.58. Aimovig faces competition from other newly launched CGRP antibodies, Lilly’s LLY Emgality and Teva’s TEVA Ajovy.

  6. Novocure Ltd (NASDAQ: NVCR) AbbVie Inc (NYSE: ABBV) Acer Therapeutics Inc (NASDAQ: ACER) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP) Aerpio ...

  7. Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat

    Zacks via Yahoo FinanceJul 31 14:44 PM

    Ligand Pharmaceuticals Incorporated LGND reported second-quarter 2019 adjusted earnings of 68 cents per share, which beat the Zacks Consensus Estimate of 61 cents. Second-quarter adjusted earnings ...

  8. Biotech ETFs in Focus on Impressive Q2 Earnings Results

    Zacks via Yahoo FinanceAug 06 20:22 PM

    Total revenues of $5.87 billion in the quarter also outpaced the Zacks Consensus Estimate of $5.68 billion. However, total revenues declined 3% year over year. The company raised the low end ...

  9. At this time, I would like to welcome everyone to the Enanta Pharmaceuticals third quarter financial results conference call. I'd now like to turn the call over to your host, Miss Carol Miceli ...

  10. Intellia Therapeutics, Inc. (NTLA) Q2 2019 Earnings Call Transcript

    Motley Fool via Yahoo FinanceAug 01 16:23 PM

    John Leonard -- President and Chief Executive Officer Yeah. We don't give many details, but for the purposes of the tox work and getting in the clinical, it's a collection of different suppliers ...

  1. Ad
    related to AbbVie Inc